A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 103
- Population
- ALL · 50 Years
- Duration
- 2014-08-28 to 2017-09-14
- Intervention
- Ranibizumab
- Comparator
- Not reported
- Outcomes measured
- Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 90. — Baseline and Day 90; Change in Subfoveal Retinal Thickness (SRT) From Baseline to Day 180 — Baseline and Day 180; Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 180 — Baseline and Day 180; Change in Central Subfield Retinal Volume (CSRV) From Baseline to Day 180 — Baseline and Day 180; Number of Patients With Intraretinal Fluid Assessed at Baseline and Day 180 — Baseline and Day 180; Number of Patients With Subretinal Fluid Assessed at Baseline and Day 180 — Baseline to Day 180; Number of Patients With Intraretinal/Subretinal Fluid Within the Central Subfield Fluid Assessed at Baseline and Day 18…; Number of Patients With Pigment Epithelial Detachments Assessed at Baseline and Day 180 — Baseline and Day 180; Number of Patients With Dry Retina Assessed at Baseline and Day 180 — Baseline and Day 180; Change in Maximum PED Height From Baseline to Day 180 — Baseline and Day 180; Change in Maximum PED Diameter From Baseline to Day 180 — Baseline and Day 180; Change in Maximum IRC Height From Baseline to Day 180 — Baseline and Day 180; Change in Best Corrected Visual Acuity (BCVA) in the Study Eye — Baseline, Day 90 and Day 180; Change in ETDRS Letters for Study Eye From Baseline to Day 180 — Baseline and Day 180; Incidence of Ocular TEAEs in the Study Eye Reported by ≥2% Patients From Baseline to Day 180 — Baseline to Day 180
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.